Budigalimab
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors[1].
Product Specifications
CAS Number
2098225-93-3
Product Name Alternative
ABBV 181; PR 1648817
UNSPSC
12352203
Target
PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/budigalimab.html
Purity
99.79
Solubility
10 mM in DMSO
Smiles
[Budigalimab]
Molecular Weight
(144.76 kDa)
References & Citations
[1]Powderly J, et al. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181) . Clin Transl Sci. 2021 Jan;14 (1) :277-287. |[2]Lambert SL, et al., Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab. J Immunother. 2022 Apr 1;45 (3) :167-179.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC550633-500 1x 500 µL
Von Willebrand Factor (3E2D10), CF555 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC741081-100 1x 100 µL
CD45RO (190-2F2.5), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400525-100 1x 100 µL
CD63 (MX-49.129.5), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC681424-500 1x 500 µL
Caldesmon, HMW (h-Caldesmon) (Smooth Muscle Marker) (CALD1/1424R), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details